Thermo Fisher Beats Estimates, Despite Industry Headwinds

Thermo Fisher Scientific exceeded Wall Street expectations with Q1 earnings of $11.01 billion, a 6% increase from last year. Growth in lab products and biopharma services drove the results, while specialty diagnostics and analytical instruments saw softer sales. Despite the strong performance, shares dropped 3.1% in premarket trading due to broader industry challenges, including cautious funding for small biotechs and weak academic research budgets, exacerbated by Trump administration cuts and grant freezes. Adjusted earnings per share reached $5.44, surpassing estimates. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5802f7c439e59571